Calliditas Therapeutics AB (OSTO:CALTX) Ending Cash Position : kr810 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Calliditas Therapeutics AB Ending Cash Position?

Calliditas Therapeutics AB's Ending Cash Position for the quarter that ended in Mar. 2024 was kr810 Mil.

Calliditas Therapeutics AB's quarterly Ending Cash Position increased from Sep. 2023 (kr787 Mil) to Dec. 2023 (kr974 Mil) but then declined from Dec. 2023 (kr974 Mil) to Mar. 2024 (kr810 Mil).

Calliditas Therapeutics AB's annual Ending Cash Position increased from Dec. 2021 (kr956 Mil) to Dec. 2022 (kr1,249 Mil) but then declined from Dec. 2022 (kr1,249 Mil) to Dec. 2023 (kr974 Mil).

Calliditas Therapeutics AB Ending Cash Position Historical Data

The historical data trend for Calliditas Therapeutics AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Ending Cash Position Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

753.54

996.30

955.51

1,249.09

973.73

Calliditas Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															1,013.60	866.18	786.88	973.73	810.32

Calliditas Therapeutics AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Calliditas Therapeutics AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1249.094	+	-275.361
	=	974

Calliditas Therapeutics AB's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	973.733	+	-163.416
	=	810

Calliditas Therapeutics AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (OSTO:CALTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (OSTO:CALTX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CALT:USA CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Calliditas Therapeutics AB (OSTO:CALTX) Headlines

No Headlines